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Hepatic fibrin(ogen) has been noted to occur after
acetaminophen (APAP)-induced liver injury in mice.
Deficiency in plasminogen activator inhibitor-1 (PAI-
1), an endogenous inhibitor of fibrinolysis, increases
APAP-induced liver injury in mice. However, the roles
of fibrinogen and fibrinolysis in APAP-induced liver
injury are not known. We tested the hypothesis that
hepatic fibrin(ogen) deposition reduces severity of
APAP-induced liver injury. APAP-induced (300 mg/kg)
liver injury in mice was accompanied by thrombin
generation, consumption of plasma fibrinogen, and
deposition of hepatic fibrin. Neither fibrinogen deple-
tion with ancrod nor complete fibrinogen deficiency
[via knockout of the fibrinogen alpha chain gene
(Fbg⁄)] affected APAP-induced liver injury. PAI-1 de-
ficiency (PAI-1⁄) increased APAP-induced liver in-
jury and hepatic fibrin deposition 6 hours after APAP
administration, which was followed by marked hem-
orrhage at 24 hours. As in PAI-1⁄ mice, administra-
tion of recombinant tissue plasminogen activator (te-
necteplase, 5 mg/kg) worsened APAP-induced liver
injury and hemorrhage in wild-type mice. In contrast,
APAP-induced liver injury was reduced in both
plasminogen-deficientmice and inwild-typemice treated
with tranexamic acid, an inhibitor of plasminogen
activation. Activation of matrix metalloproteinase 9
(MMP-9) paralleled injury, but MMP-9 deficiency did
not affect APAP-induced liver injury. The results indi-
cate that fibrin(ogen) does not contribute to develop-
ment of APAP-induced liver injury and suggest rather
that plasminogen activation contributes to APAP-
induced liver injury. (Am J Pathol 2012, 180:2321–2329;
http://dx.doi.org/10.1016/j.ajpath.2012.02.011)Acetaminophen (APAP) overdose is a leading cause of
drug-induced liver failure in the United States.1 APAP
bioactivation by hepatocytes to the highly reactive N-
acetyl-p-benzoquinone imine (NAPQI) metabolite results
in intracellular macromolecule modification and mito-
chondrial dysfunction, which are key initiating events of
the subsequent hepatocellular necrosis.1 The progres-
sion of APAP-induced liver injury is associated with nu-
merous events, including activation of the blood coagu-
lation cascade. Thrombin generation is evident in
patients with acute APAP overdose and in mouse models
of acute APAP-induced liver injury.2,3 In mice given a
hepatotoxic dose of APAP, tissue factor-dependent
thrombin generation is associated with consumption of
circulating fibrinogen and deposition of insoluble fibrin
clots in the liver.2 However, the role of fibrin(ogen) in
APAP-induced liver injury is not known.
Fibrin deposition is determined by a balance of proco-
agulant (ie, thrombin) and fibrinolytic pathways. Tissue
plasminogen activator (tPA) and urokinase plasminogen
activator (uPA) convert plasminogen to the fibrinolytic
enzyme plasmin, which degrades fibrin clots.4 The pri-
mary physiological inhibitor of uPA and tPA is plasmino-
gen activator inhibitor 1 (PAI-1).5 Hepatic PAI-1 mRNA
expression and plasma PAI-1 protein levels increase dra-
matically after APAP administration.2,6,7 A recent study
indicated that APAP-induced liver injury is increased in
PAI-1⁄ mice, suggesting a protective role of PAI-1 in
APAP hepatotoxicity.6 Bajt et al6 proposed the intriguing
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PAI-1/ mice precipitates APAP-induced hemorrhage
and increased parenchymal cell injury, although the ef-
fect of PAI-1 deficiency on hepatic fibrin deposition is not
known. Moreover, the exact role of fibrin and fibrinolytic
enzymes has not been determined in APAP-induced liver
injury.
Although exaggerated fibrinolysis and a reduction in
hepatic fibrin composition is one mechanism whereby
PAI-1 deficiency could increase APAP-induced liver in-
jury, fibrin-independent mechanisms cannot be ex-
cluded. For example, plasmin can directly activate pro-
matrix metalloproteinase-2 (MMP-2) and pro-MMP-9.8–12
Expression and activity of MMP-2 and MMP-9 were
shown to be increased in livers of mice treated with
APAP, and an inhibitor of these gelatinases significantly
reduced APAP-induced liver injury.13 Accordingly, one
potential fibrin-independent mechanism whereby in-
creased plasmin could contribute to APAP-induced liver
injury is activation of the MMPs. However, it is not cur-
rently known whether the fibrinolytic system contributes
to MMP activation after APAP overdose in mice.
In the present study, we characterized the time course
of coagulation and hepatic fibrin deposition in a mouse
model of APAP overdose and used two strategies to
determine the role of fibrin(ogen) in APAP-induced liver
injury. Moreover, using a combination of gene-targeted
mice and specific pharmacological tools, we explored
the role of plasminogen activation on MMP activity and on
the progression of APAP hepatotoxicity by using pharma-
cological and genetic approaches to modulate plasmin-
ogen activators.
Materials and Methods
Mice
All studies were performed with male mice, 8 to 16 weeks
of age. Wild-type C57Bl/6J mice were purchased from
the Jackson Laboratory (Bar Harbor, ME). PAI-1⁄ mice
(B6.129S2-Serpine1tm1Mlg/J mice), MMP-9⁄ mice
[B6.FVB(Cg)-Mmp9tm1Tvu/J], and age-matched wild-type
C57Bl/6J mice were purchased from the Jackson Labo-
ratory. Fibrinogen -chain-deficient mice (Fbg⁄) and
heterozygous control mice (Fbg⁄) mice back-crossed
six generations onto a C57Bl/6J background [kindly pro-
vided by Dr. Jay Degen (Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH)] were maintained at the
University of Kansas Medical Center in a facility accred-
ited by the Association for Assessment and Accreditation
of Laboratory Animal Care International. Mice were
housed at an ambient temperature of 22°C with 14/10-
hour light/dark cycles and were provided water and ro-
dent chow ad libitum (Teklad 8604; Harlan, Indianapolis,
IN). Plg-deficient mice (Plg⁄) or wild-type control mice
(Plg⁄) backcrossed for eight generations on a C57Bl/6J
background were maintained at the Cincinnati Children’s
Hospital Medical Center. All animal procedures were ap-
proved by the Institutional Animal Care and Use Commit-tee of the University of Kansas Medical Center or the
Cincinnati Children’s Hospital Medical Center.
APAP Model and Pharmacological Interventions
Mice fasted for approximately 15 hours were given 300
mg/kg APAP (at 30 L/g body weight) or vehicle (sterile
saline solution) via intraperitoneal injection and food was
returned. To deplete fibrinogen, mice were given ancrod
(1.5 U i.p.; National Institute for Biological Standards and
Control, Potters Bar, UK) or vehicle (300 L sterile PBS
i.p.) 2 hours before APAP treatment. Tenecteplase (TNK;
5 mg/kg at 10 L/g body weight; a kind gift from Genen-
tech, San Francisco, CA) or saline vehicle was given 2
hours after APAP administration by retro-orbital injection
under isoflurane anesthesia. Tranexamic acid (600
mg/kg at 30 L/g body weight; Spectrum Chemicals &
Laboratory Products, New Brunswick, NJ) or saline vehi-
cle was given intraperitoneally 2 hours after APAP treat-
ment. At various times after APAP administration, mice were
anesthetized using isoflurane. Blood was collected from the
caudal vena cava into sodium citrate (final, 0.38%) or an
empty syringe for the collection of plasma and serum, re-
spectively. The liver was removed, washed in saline, and
the intact gall bladder removed. The left medial lobe of the
liver was affixed to a cork with optimal cutting temperature
compound and frozen for 3 minutes in liquid nitrogen-
chilled isopentane. Sections of the left lateral lobe were
fixed in neutral-buffered formalin for 48 hours before routine
processing. The remaining liver was cut into 100-mg pieces
and frozen in liquid nitrogen.
Histopathology and Fibrin Staining
Formalin-fixed livers were sectioned at 5 m, stained with
H&E, and evaluated under light microscopy. Three sec-
tions of liver from the left lateral lobe were evaluated from
each animal. The area of hepatocellular necrosis in sev-
eral low-magnification (40) images encompassing the
total area of the three sections was determined by J.P.L.
in a masked fashion as described previously,14 using
Scion Image software version 4.0.2 (Scion Image Corp.,
Gaithersburg, MD). To determine percent necrotic area,
the area of liver occupied by necrosis was compared with
the total area of liver in each image. Immunofluorescent
staining for insoluble hepatic fibrinogen was performed as
described previously,15 using a rabbit anti-human fibrino-
gen antibody (A0080; Dako, Carpinteria, CA). The primary
antibody was detected by the addition of goat anti-rabbit
IgG conjugated to Alexa Fluor 488 (A11008; Invitrogen,
Carlsbad, CA) and evaluated under fluorescent micros-
copy.
Clinical Chemistry
The serum activity of alanine aminotransferase (ALT) was
determined using a commercially available reagent (Thermo
Fisher, Waltham, MA). Plasma thrombin-antithrombin levels
were determined using a commercial enzyme-linked immu-
nosorbent assay kit (Siemens Healthcare Diagnostics,
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Infinite M200 plate reader (Tecan, Durham, NC).
Zymography
Gelatinase (MMP-2 and MMP-9) activity was determined
using gelatin zymography. Approximately 100 mg of fro-
zen liver tissue was homogenized in ice-cold 50 mmol/L
Tris-HCl buffer (pH 7.4) containing 150 mmol/L NaCl, 5
mmol/L CaCl2, and 1% Triton X-100. The homogenate was
subjected to centrifugation at 9000  g for 30 minutes at
4°C, supernatant was collected, and protein concentration
determined using a commercial protein assay kit (DC; Bio-
Rad Laboratories, Hercules, CA). Supernatant containing
50 g total protein was mixed with an equal volume of 2
Laemmli sample buffer lacking -mercaptoethanol (Bio-
Rad Laboratories) and subjected to electrophoresis in
Ready Gel zymogram gels with gelatin (Bio-Rad Laborato-
ries). After electrophoresis, SDS was removed from the gels
by three 20-minute washes with zymogram renaturation buf-
fer (2.5% Triton X-100; Bio-Rad Laboratories). The gels
were then incubated in zymogram development buffer (50
mmol/L Tris-HCl, pH 7.5, 200mmol/L NaCl, 5mmol/L CaCl2;
Bio-Rad Laboratories) at 37°C without shaking for 48 hours.
Gels were stained with Coomassie stain (Invitrogen), and
MMPs were identified by their ability to digest gelatin (clear
bands) and by their apparent molecular weights. Gel im-
ages were captured by a VersaDoc imaging system (Bio-
Rad Laboratories) and converted to grayscale. Densitome-
try was performed using Quantity One software (Bio-Rad
Laboratories).
Statistical Analysis
Comparison of two groups was performed using Stu-
dent’s t-test. Comparison of three or more groups wasperformed using one- or two-way analysis of variance, as
appropriate, and the Student-Newman-Keuls post hoc
test. Data not conforming to a normal distribution were
log10-transformed before statistical evaluation. Statistical
outliers identified by Grubb’s test (P  0.05) were ex-
cluded from further statistical analysis. The criterion for
statistical significance was P  0.05.
Results
Time Course of Coagulation Cascade Activation
and Hepatotoxicity in APAP-Treated Mice
Administration of APAP (300 mg/kg) caused liver injury,
as evidenced by increased serum ALT activity, with peak
activity evident after 24 hours (Figure 1A). Increased se-
rum ALT activity was accompanied by centrilobular hepa-
tocellular necrosis (data not shown). Plasma thrombin-anti-
thrombin levels, an indicator of thrombin generation,
increased dramatically after APAP administration, indicat-
ing marked and rapid activation of the coagulation cascade
(Figure 1B). In agreement with previous report,2 increased
thrombin-antithrombin levels were accompanied by a de-
crease in plasma fibrinogen levels (Figure 1C) and an in-
crease in hepatic fibrin deposition within areas of hepato-
cellular necrosis as early as 2 hours (Figure 1, D–H). Taken
together, the results indicate that APAP hepatotoxicity in
mice is associated with coagulation cascade activation,
fibrinogen consumption, and hepatic fibrin deposition.
Fibrin(ogen) Does Not Contribute to Acute
APAP-Induced Liver Injury
To determine the role of fibrin(ogen) in APAP-induced liver
injury, we used two independent approaches. First, circulating
Figure 1. Time course of coagulation cascade
activation and hepatotoxicity in APAP-treated
mice. Fasted wild-type mice were given a toxic
dose of APAP (300 mg/kg i.p.) or saline vehicle
(time 0); samples were collected at 2, 6, 24, and
48 hours. Levels of serum ALT activity (A),
plasma thrombin-antithrombin (TAT) (B), and
plasma fibrinogen (C) were determined. D–H:
Representative photomicrographs of hepatic fi-
brin (dark) staining at 0, 2, 6, 24, and 48 hours
after APAP treatment. Data are expressed as
means  SEM. *P  0.05 versus saline-treated
control mice. n  5 mice per group. Original
magnification, 100.fibrinogen was depleted before APAP treatment by adminis-
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ically cleaves circulating fibrinogen.16 Compared with PBS
vehicle-pretreated mice, pretreatment of mice with ancrod re-
ducedhepatic fibrin deposition after APAPadministration at 24
hours (Figure 2, B and C). However, ancrod pretreatment had
no effect on serum ALT activity at this time in APAP-treated
mice (Figure 2A). Next, we used mice lacking the fibrinogen
-chain gene (Fbg⁄mice), which completely lack circulating
fibrinogen.17 As expected, hepatic fibrin deposition was not
detected in Fbg⁄mice after APAPadministration (Figure 2, E
and F), confirming the absence of fibrinogen protein and the
specificity of the immunofluorescent staining. In agreement
with our fibrinogen depletion studies, complete fibrinogen de-
ficiency did not affect APAP-induced liver injury, as indicated
by serum ALT activity (Figure 2D). Overall, these studies sug-
gest that fibrin(ogen) is not a criticalmediator of APAP-induced
liver injury in mice.
PAI-1 Deficiency Enhances Liver Injury,
Hemorrhage, and Fibrin Deposition in
APAP-Treated Mice
Bajt et al6 reported that APAP-induced liver injury was in-
creased in PAI-1-deficient (PAI-1⁄) mice. In agreement
with their findings, we found that APAP-induced liver injury,
as indicated by increased serum ALT activity (Figure 3A)and centrilobular necrosis (data not shown), was signifi-
cantly increased at 6 hours after APAP administration in
PAI-1⁄ mice. In association with increased necrosis,
hepatic fibrin deposition was increased in PAI-1⁄ mice
at this time point (Figure 3, B and C). Serum ALT activity
also trended higher in APAP-treated PAI-1⁄ mice
relative to wild-type control mice at 24 hours (Figure 3D).
In agreement with a previous study,6 marked hemor-
rhage was evident in livers of PAI-1⁄ mice by 24 hours
(see Supplemental Figure S1 at http://ajp.amjpathol.org).
Fibrin was evident in areas of necrosis in both wild-type
and PAI-1⁄ mice at 24 hours (Figure 3, E and F). These
results indicate that increased liver injury in APAP-treated
PAI-1⁄ mice is not a consequence of reduced hepatic
fibrin deposition.
TNK (Recombinant Human tPA) Administration
Enhances APAP-Induced Liver Injury in Mice
Enhanced APAP-induced liver injury in PAI-1⁄ mice
suggests that increased plasminogen activator activity
could worsen APAP-induced liver injury. To test this hy-
pothesis, we used TNK, a recombinant human tPA.18
Administration of TNK (5 mg/kg) alone to wild-type mice
had no effect on serum ALT levels (Figure 4A) or liver
histopathology (data not shown). To minimize potential
Figure 2. Fibrin(ogen) does not contribute to
acute APAP-induced liver injury. A–C: Fasted
wild-type mice were treated with ancrod (1.5 U)
or vehicle (300 L sterile PBS) at 2 hours before
treatment with APAP (300 mg/kg); samples were
collected at 24 hours and serum ALT activity (A)
was determined. D–F: Fasted Fbg⁄ control
mice and Fbg⁄ were treated with APAP (300
mg/kg); samples were collected at 24 hours. Se-
rum ALT activity was determined (D). B, C, E,
and F: Representative photomicrographs of fi-
brin (dark) staining in livers after APAP treat-
ment. Data are expressed as means  SEM. n 
7 to 12 mice per group. Original magnification,
100.
Figure 3. PAI-1-deficiency enhances liver injury
and fibrin deposition in APAP-treated mice.
Fasted wild-type (PAI-1/) or PAI-1⁄ mice
were treated with APAP (300 mg/kg); samples
were collected at 6 or 24 hours. Levels of serum
ALT activity (A and D) were determined. B, C, E,
and F: Representative photomicrographs of fi-
brin (dark) staining in livers from APAP-treated
wild-type (B and E) and PAI-1⁄ mice (C and
F). Data are expressed as means  SEM. *P 
0.05 versus wild-type mice. n  3 or 4 mice per
group. Original magnification, 100.
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TNK 2 hours after APAP injection. TNK administration did
not affect serum ALT activity at 6 hours after APAP ad-
ministration (Figure 4A). However, increased hemorrhage
was evident in areas of necrosis at 6 hours in APAP-
treated mice given TNK (Figure 4, B and C). Serum ALT
activity was significantly increased at 24 hours in mice
treated with APAP and TNK, compared with mice treated
with APAP alone (Figure 4A). The increase in serum ALT
activity at 24 hours in TNK-treated mice was accompa-
nied by a dramatic increase in hemorrhage (Figure 4, D
and E), which closely resembled that observed in livers of
PAI-1-deficient mice treated with APAP for 24 hours (see
Supplemental Figure S1 at http://ajp.amjpathol.org; see
also Bajt et al6). These data suggest that exaggerated
activation of the plasminogen activators increases APAP-
induced liver injury and hemorrhage.
Pharmacological Inhibition of Plasminogen
Activation and Genetic Plasminogen Deficiency
Reduces APAP-Induced Liver Injury
One mechanism whereby plasminogen activators could
Figure 4. TNK (recombinant human tPA) administration enhances APAP-
induced liver injury in mice. Fasted wild-type mice were treated with APAP
(300 mg/kg) or saline vehicle, and 2 hours later were given TNK (5 mg/kg
retro-orbital injection) or saline vehicle. A: Serum levels of ALT activity were
determined at 6 and 24 hours after APAP treatment. B–E: Representative
photomicrographs of H&E-stained liver sections at 6 or 24 hours from mice
treated with APAP and given TNK or saline vehicle. Data are expressed as
means SEM. *P  0.05 versus APAP-treated mice given saline vehicle. n 
3 to 8 mice per group. Original magnification, 100.contribute to APAP-induced liver injury is through conver-sion of plasminogen to plasmin.8,9 To identify whether
plasmin participates in APAP-induced liver injury, we
used tranexamic acid, which binds plasminogen and in-
hibits its activation by plasminogen activators.19 Admin-
istration of tranexamic acid alone did not alter serum ALT
levels or liver histopathology (Figure 5, A and B). To
minimize potential effects of tranexamic acid on metab-
olism of APAP, tranexamic acid was administered 2 hours
after APAP injection. Compared with saline vehicle-
treated mice, tranexamic acid administration reduced se-
rum ALT activity at 6 and 24 hours after APAP adminis-
tration (Figure 5A), although this difference did not
Figure 5. Inhibition of plasminogen activation and complete plasminogen
deficiency reduces APAP-induced liver injury. A–D: Fasted wild-type mice
were treated with APAP (300 mg/kg) or saline vehicle. Two hours later, mice
were treated with tranexamic acid (TA; 600 mg/kg i.p.) or saline vehicle.
Serum ALT activity (A) was determined at 6 and 24 hours after APAP treat-
ment; area of necrosis (B) was determined 24 hours after APAP treatment.
C and D: Representative photomicrographs of H&E-stained liver sections at
24 hours from mice treated with APAP and then treated with saline vehicle or
tranexamic acid (TA). E–H: Fasted wild-type (Plg⁄) or plasminogen-defi-
cient (Plg⁄) mice were treated with APAP (300 mg/kg) or saline vehicle; samples
were collected at 24 hours. Serum ALT activity (E) and area of necrosis (F) were
determined. G and H: Representative photomicrographs of H&E-stained liver sec-
tions from APAP-treated Plg⁄ or Plg⁄ mice at 24 hours after APAP treatment.
Data are expressed as means  SEM. *P  0.05 versus APAP-treated mice given
⁄saline vehicle (A and B) or versus APAP-treated Plg mice (E and F). n 3 to 10
mice per group. Original magnification, 100.
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importance, tranexamic acid treatment significantly re-
duced the area of centrilobular necrosis in APAP-treated
mice at 24 hours (Figure 5, B–D). Similar to pharmaco-
logical inhibition of plasminogen activation by tranexamic
acid, complete plasminogen deficiency significantly re-
duced APAP-dependent liver injury at 24 hours, as indi-
cated by a reduction in serum ALT activity (Figure 5E)
and area of centrilobular necrosis (Figure 5, F–H). These
results suggest that plasminogen contributes to APAP-
induced liver injury.
Role of Plasminogen Activators in MMP-9
Activation in APAP-Treated Mice
One mechanism whereby plasmin could contribute to
APAP-induced liver injury is by activating pro-MMP-2 and
pro-MMP-9, enzymes implicated in the progression of
APAP-induced liver injury.8,9,13 Accordingly, we deter-
mined the time course of gelatinase (MMP-2/9) activation
in APAP-treated mice and the effect of genetic and phar-
macological modulation of the plasminogen activators on
MMP-2/9 activity. As indicated by gelatin zymography,
MMP-9 activity was increased in livers of APAP-treated
mice as early as 6 hours and remained elevated at 48
hours (Figure 6, A and B). However, we found no detect-
able increase in MMP-2 activity in mice treated with APAP
(data not shown). Of note, MMP-9 activity in livers of
APAP-treated mice at 6 hours was increased by PAI-1
Figure 6. Role of plasminogen activators in MMP-9 activation in APAP-
treated mice. Representative zymogram images (A, C, E, and G) and their
respective zymogram quantification (B, D, F, and H) from liver homogenates
of APAP-treated mice. A: Gelatinase activity was determined from homoge-
nates of APAP-treated wild-type mice various times after APAP treatment.
C–H: Gelatinase activity was determined at 6 hours in liver homogenates
from PAI-1⁄ and PAI-1⁄mice(C andD), wild-type mice treated with TNK
or vehicle (E and F), and wild-type mice treated with tranexamic acid (TA) or
vehicle(G and H). Data are expressed as means  SEM (B) or as means 
SEM (D, F, and H). *P  0.05 versus the respective control. n  3 to 5 mice
per group.deficiency (Figure 6, C and D) and by TNK treatment
(Figure 6, E and F), suggesting that enhanced activation
of plasminogen activators increases MMP-9 activation in
APAP-treated mice. Tranexamic acid administration signif-
icantly reduced hepatic MMP-9 activity in APAP-treated
mice at 6 hours (Figure 6, G and H). These data indicate
that MMP-9 is activated after APAP-induced liver injury.
MMP-9 Deficiency Does Not Protect Against
APAP-Induced Liver Injury
Ito et al13 reported that APAP-induced liver injury was
reduced in mice given a MMP-2/9 inhibitor (2-[(4-biphe-
nylsulfonyl)amino]-3-phenyl-propionic acid). In that light,
and because we identified an increase in MMP-9 activity
in livers of APAP-treated mice, we further evaluated
whether MMP-9 could contribute to APAP-induced liver
injury. Hepatic MMP-9 activity was not detectable by
gelatin zymography in MMP-9⁄ mice, confirming spec-
ificity of this assay (Figure 7A). Of note, APAP-induced
liver injury was similar inMMP-9⁄ mice and in wild-type
control mice, as indicated by serum ALT activity (Figure
7B). These results indicate that MMP-9 does not contrib-
ute to the development of acute APAP-induced liver in-
jury.
Discussion
The role of PAI-1 in liver injury is model dependent. For
example, whereas PAI-1 deficiency reduces liver injury
after bile duct ligation,20 PAI-1/mice are more suscep-
tible to carbon tetrachloride-induced liver injury.21 The
expression of PAI-1 mRNA is increased rapidly in liver
after APAP overdose in mice,6,7 and PAI-1 protein levels
increase markedly in the plasma.2 In agreement with the
report of Bajt et al,6 we found that APAP-induced liver
injury was increased in PAI-1⁄ mice, suggesting that
PAI-1 is a protective factor in APAP hepatotoxicity. Of
Figure 7. MMP-9 deficiency does not protect against APAP-induced liver
injury. Fasted wild-type (MMP-9⁄) and MMP-9-deficient (MMP-9⁄) mice
were treated with APAP (300 mg/kg); samples were collected at 24 hours. A:
Representative gelatin zymogram (95 kDa) from liver homogenates of
APAP-treated MMP-9⁄ or MMP-9⁄mice at 24 hours after APAP treatment.
B: Serum ALT activity was determined 24 hours after APAP treatment. n  5
to 9 mice per group.importance, generation of the toxic metabolite NAPQI
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genotype does not affect APAP metabolism. It has been
suggested that the presence of marked hemorrhage in
livers of APAP-treated PAI-1⁄ mice could occur as a
consequence of reduced hepatic fibrin deposition and a
failure to maintain normal hemostasis.6 Of importance, we
found that hepatic fibrin levels actually increased in associ-
ation with increased hepatocellular injury in PAI-1⁄ mice
at 6 hours, and fibrin remained present in livers of
APAP-treated PAI-1⁄ mice at 24 hours. These find-
ings suggest that increased APAP hepatotoxicity in
PAI-1⁄ mice is not a consequence of reduced fibrin
levels in liver.
Hepatic fibrin deposition occurs in numerous models
of xenobiotic-induced liver injury,2,15,22–25 but the mech-
anistic contribution of fibrinogen has not been deter-
mined in most models. In the present study, we used
two independent approaches to evaluate the role of
fibrin(ogen) in APAP hepatotoxicity: either depletion of
fibrinogen with ancrod or use of Fbg⁄ mice, which
completely lack circulating fibrinogen protein.17 Neither
fibrinogen depletion nor complete fibrinogen deficiency
affected APAP-induced liver injury at 24 hours, suggest-
ing that fibrinogen does not contribute to acute APAP
hepatotoxicity. This is in contrast to other models, in
which fibrinogen has been shown to be either damaging
or hepatoprotective.14,26 Of importance, the finding that
fibrinogen is not required for acute APAP hepatotoxicity
supports the hypothesis that a change in hepatic fibrin
clearance is not the primary mechanism of increased
APAP hepatotoxicity in PAI-1-deficient mice.
To further delineate the effect of enhanced plasmino-
gen activation on APAP-induced liver injury, we used
TNK, a recombinant human tPA. We selected to admin-
ister TNK at 2 hours after APAP treatment, to avoid the
possibility of interfering with APAP metabolism, NAPQI
generation, and glutathione depletion, the vast majority of
which occurs within 60 minutes of APAP administra-
tion.27,28 Mirroring changes in livers of APAP-treated
PAI-1⁄ mice, hepatocellular injury and hemorrhage
were increased by TNK administration, consistent with
the hypothesis that APAP-induced liver injury is in-
creased by exaggeration of plasminogen activator activ-
ity. However, it cannot be concluded from these studies
that endogenous tPA is the critical plasminogen activator
participating in APAP-induced liver injury. Both uPA and
tPA can convert plasminogen to plasmin, but each plas-
minogen activator generally serves different biological
functions. tPA is an important regulator of fibrin degrada-
tion and vascular hemostasis, whereas uPA generally
participates in tissue repair and extracellular matrix re-
modeling.5 Of note, tPA directly binds fibrin polymers,
and this enhances its enzymatic activity by several hun-
dredfold.5 Insofar as fibrin deficiency did not affect
APAP-induced liver injury, this could suggest that uPA
rather than tPA is the critical endogenous plasminogen
activator during APAP-induced liver injury. Additional
studies would be required to determine the relative con-
tribution of uPA and tPA in APAP-induced liver injury.
Studies in PAI-1-deficient mice indicate that PAI-1 limits
APAP-induced liver injury, and our studies with TNK adminis-tration support the hypothesis that exaggerated plasminogen
activation worsens APAP-induced liver injury. To determine
whether administration of an inhibitor of plasminogen activa-
tion could confer additional protection against APAP-induced
liver injury under conditions in which PAI-1 was present, we
used tranexamic acid, an antifibrinolytic drug that prevents the
conversion of plasminogen to plasmin.19 As in our studies with
TNK, tranexamic acid was given 2 hours after APAP, to avoid
any potential effect on APAP metabolism. Our results suggest
that the activation of plasmin, even in wild-type mice with suf-
ficient levels of PAI-1, contributes to the progression of liver
injury in APAP-treated mice. Of importance, we found that
complete genetic plasminogen deficiency also reduced
APAP-induced liver injury. However, these results do not iden-
tify which plasminogen activator (tPA and/or uPA) is responsi-
ble for activating plasminogen during APAP-induced liver in-
jury. Additionally, these studies do not test the possibility that
tPA and/or uPA also contribute to the progression of APAP-
induced liver injury in a plasminogen-independent manner.
These studies are the subject of ongoing investigation in our
laboratory.
Our findings indicate that fibrinogen is not involved in
the development of APAP-induced liver injury. However,
the results suggest that plasmin, the primary endogenous
fibrinolytic enzyme, contributes to APAP-induced liver in-
jury. One fibrin-independent mechanism whereby plas-
min might contribute to APAP toxicity is through activation
of pro-MMP-2/9. Plasmin has been shown to contribute to
conversion of both pro-MMP2 and pro-MMP9 to their
active forms.8–12 Ito et al13 reported that hepatic MMP-2
and MMP-9 expression and activity are increased in liv-
ers of mice after APAP overdose.13 In accord with their
findings, we found that MMP-9 activity increased in liver
as early as 6 hours after APAP administration. However,
we were not able to detect an increase in MMP-2 activity
after APAP administration (data not shown) and we there-
fore focused on the possibility that plasmin-dependent
MMP-9 activation could contribute to APAP hepatotoxic-
ity. In contrast to a previous study demonstrating that a
pharmacological inhibitor of MMP-2/9 reduced APAP
hepatotoxicity,10 MMP-9 deficiency did not affect APAP
induced liver injury in the present study. Notable differences
between the present study usingMMP-9-deficient mice and
a previous study using a pharmacological inhibitor of
MMP-9 include their use of DMSO as the solvent for the
MMP inhibitor, a compound known to affect APAP metab-
olism and glutathione depletion.28 The fast before APAP
administration was more extensive in that study (24 hours,
compared with 15 hours in the present study), and both the
dose and the route of APAP administration differed between
the two studies. Our studies with MMP-9⁄ mice strongly
suggest that the protection observed previously cannot be
attributed to inhibition of MMP-9.
In the clinic, patients who present with APAP overdose
arrive with varying degrees of liver injury and at various
stages of injury progression. Our data suggest that a
PA-plasmin pathway participates in the early progression
of APAP-induced liver injury in a mouse model. Inhibition
of this pathway could provide a therapeutic benefit to
patients during the early progression phase of APAP
toxicity. However, the fibrinolytic system and MMPs have
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wound healing processes. Deficiency in plasminogen
has been shown to derange the wound healing process,
including in chronic liver injury.29 A previous study
showed that impaired liver regeneration in plasminogen-
deficient mice was not affected by a combined defi-
ciency of fibrinogen,30 suggesting that plasminogen con-
tributes to liver repair in a fibrinolysis-independent
mechanism in that model. Although we found that fibrin-
ogen deficiency does not affect acute APAP hepatotox-
icity development, we cannot exclude a role for fibrino-
gen in the resolution of APAP-induced liver injury.
Similar questions arise about the potential for differen-
tial roles of plasminogen activators and MMPs during the
development and recovery phases of APAP-induced liver
injury. Accelerated injury resolution has been described
in PAI-1⁄ mice in a dermal injury model.31 Of impor-
tance, uPA is known to activate hepatocyte growth factor,
a critical cytokine that promotes liver regeneration.32 Bajt
et al6 reported that increased liver injury 24 hours after
APAP administration in PAI-1⁄ mice was accompanied
by a decrease in hepatic PCNA protein expression, sug-
gesting that these mice have delayed liver regeneration.
In that same study, however, PAI-1⁄ mice with dramat-
ically increased liver injury recovered alongside wild-type
mice by 48 hours, suggesting that those mice had en-
hanced liver regeneration in the recovery phase of
APAP.6 Further experiments are needed to determine the
role or roles of fibrinogen, fibrin, and fibrinolytic enzymes
in the resolution and repair of APAP-induced liver injury.
In summary, we have shown through genetic and phar-
macological interventions that fibrin(ogen) are not involved
in the development of APAP hepatotoxicity in mice. Further-
more, we found that both genetic (PAI-1⁄) and pharma-
cological (TNK) interventions that increase plasminogen ac-
tivator activity also increase APAP-induced liver injury and
hemorrhage. Of importance, inhibition of plasminogen ac-
tivation with tranexamic acid and complete plasminogen
deficiency reduced liver injury in APAP-treated mice.
Taken together, our findings indicate that the plasmino-
gen activators and plasmin contribute to APAP-induced
liver injury development in a fibrin(ogen)-independent
manner. Inhibition of the PA-plasmin pathway may serve
as a potential therapeutic target to limit acute liver injury
development in patients presenting with APAP overdose.
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